RT Journal Article SR Electronic T1 Beta regression with spatio-temporal effects as a tool for hospital impact analysis of initial phase epidemics: the case of COVID-19 in Spain JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.27.20141614 DO 10.1101/2020.06.27.20141614 A1 Gil Jannes A1 Jesús Barreal YR 2020 UL http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141614.abstract AB COVID-19 has put an extraordinary strain on medical staff around the world, but also on hospital facilities and the global capacity of national healthcare systems. In this paper, Beta regression is introduced as a tool to analyze the rate of hospitalization and the proportion of Intensive Care Unit admissions over both hospitalized and diagnosed patients, with the aim of explaining as well as predicting, and thus allowing to better anticipate, the impact on hospital resources during an early-phase epidemic. This is applied to the initial phase COVID-19 pandemic in Spain and its different regions from 20-Feb to 08-Apr of 2020. Spatial and temporal factors are included in the Beta distribution through a precision factor. The model reveals the importance of the lagged data of hospital occupation, as well as the rate of recovered patients. Excellent agreement is found for next-day predictions, while even for multiple-day predictions (up to 12 days), robust results are obtained in most cases in spite of the limited reliability and consistency of the data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone